Posted by Michael Wonder on 13 Jul 2017
Proposed revision to the procedure for the CADTH Common Drug Review and the CADTH Therapeutic Review Framework
13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common Drug Review and the Therapeutic Review Framework and Process.
Under the current Procedure for the CADTH Common Drug Review (August 2014) and the Therapeutic Review Framework and Process (August 2016), existing recommendations that have been issued through the CDR process can only be updated following the initiation of the request for advice process.
To enhance the efficiency of CADTH’s drug portfolio and to reduce the burden on manufacturers and patient groups, CADTH is proposing an update to the Procedure for the CADTH Common Drug Review and the Therapeutic Review Framework and Process to permit CDEC to revise existing recommendations from the CDR process as part of the therapeutic review process. This revision will eliminate the need to initiate the request for advice process and result in a more efficient process for all stakeholders. In developing the proposed process, CADTH has consulted with the CDR-participating drug plans.
